Multikinase inhibitors (MKIs) have shown efficacy in endocrine neoplasms and synergism with immune-checkpoint inhibitors (ICI) has been noted in other tumors. This is a prospective, multi-center, open-label, Simon 2 stage optimal design, phase II study including patients with advanced and refractory endocrine and neuroendocrine neoplasms in 6 cohorts: lung well-differentiated neuroendocrine tumors (lungNET), anaplastic thyroid cancer (ATC), adrenocortical carcinoma (ACC), pheochromocytoma/paraganglioma (PPGL), well-differentiated gastroenteropancreatic NET (GEP-NET), and grade 3 extrapulmonary neuroendocrine neoplasms (G3 EP-NEN). Patients received atezolizumab 1200 mg IV Q3W plus cabozantinib 40 mg/day PO until disease progression or unacceptable toxicity. The primary objective was overall response rate (ORR) by RECIST 1.1. From October 2020 to December 2022, 93 patients were included. ORR was 14.3% (95% CI:1.8-42.8) in ATC (N=14); 8.3% (95% CI:1.0-27.0) in ACC (N=24); 15.4% (95% CI:1.9-45.5) in PPGL (N=13) and 16.7% (95% CI: 4.7-37.4) in GEP-NET (N=24). LungNET and G3 EP-NEN had no responses. Duration of response (DoR) was 20.4 months in ATC; 13.1 months in ACC; 12.2 months in PPGL and 15.8 months in GEP-NET. Survival rates at 12 months in ATC and ACC were 47.6 %and 47.6 % respectively. No unexpected toxicity was observed. Cabozantinib and atezolizumab were safely administered and showed promising ORR and preliminary long-term survival rates were observed in aggressive and pretreated ACC and ATC, which warrants further investigation.
Capdevila et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: